Synbio International, Inc. (OTC: SYIN) has taken a significant step toward generating revenue by entering into a strategic licensing, manufacturing, supply, and revenue sharing agreement with MD PHD Wellness, Inc. The deal grants Synbio exclusive rights to commercialize MD PHD Wellness' proprietary nutraceutical formulations in the United States and Canada. The first product to be marketed under Synbio's Healing Force™ brand is an anti-anxiety formulation, with a framework in place to evaluate and commercialize additional wellness products over time.
This partnership is particularly important because it provides Synbio with immediate access to proprietary products without the time and cost burden of developing formulations from scratch. As Claudio Solitario, CEO of Synbio International, stated, "Rather than building a nutraceutical business product by product, we have established a strategic partnership that combines MD PHD's product development and manufacturing expertise with Synbio's commercialization capabilities." This approach allows the company to focus on building brands, generating sales, and expanding market presence, which are critical for near-term revenue generation.
The global nutraceutical market is expanding rapidly, and this agreement positions Synbio to participate through a growing portfolio of scientifically developed products. At the same time, Synbio continues to advance its longer-term AI-driven healthcare technologies, creating a dual-track strategy that pairs near-term commercial revenue with future innovation.
MD PHD Wellness brings substantial scientific leadership to the partnership. The company was founded by Dr. Robert Lawrence, who holds two Ph.D. degrees in Nuclear Physics and Biomedical Engineering and has extensive experience in medicine, biomedical engineering, microbiology, pharmacology, and nutraceutical development. Co-founder Dr. David Anderson, an experienced physician and researcher, played a key role in developing the proprietary formulations licensed to Synbio. His background includes serving as a Research Physician and Senior Research Scientist at a prominent New York-based university, where he participated in the evaluation and scientific validation of therapeutics and nutraceuticals.
Under the agreement, MD PHD Wellness will handle product development, manufacturing, quality assurance, and supply chain management, while Synbio will manage branding, marketing, sales, and distribution. Profits from product sales will be shared after recovery of approved costs. This structure is designed to be efficient and scalable, allowing both companies to leverage their strengths.
For Synbio, this deal is a transformational milestone. It not only provides a near-term revenue stream but also establishes a long-term product pipeline. The company plans to launch its nutraceutical products directly to consumers online in 2026, generating early revenue while its AI-driven mental health software continues through validation. By securing these exclusive rights, Synbio is positioning itself to become a diversified healthcare company with multiple avenues for growth.
